Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Phase I/II Dose-Escalation Study of Lenalidomide in Combination with R-GDP for Treatment of Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Followed By Maintenance Lenalidomide

Colin Phipps, MD, Chandramouli Nagarajan, MBBS, Lawrence Ng, MBBS, Jane L Chua, Yunxin Chen, MBBS, Shin Yeu Ong, MD, Melinda Si Yun Tan, MBBS, Nicholas Francis Grigoropoulos, MD PhD, Sathish Gopalakrishnan, MD, Heng Joo Ng, MBBS, William YK Hwang, MBBS, Yeow Tee Goh, MBBS, Yuh Shan Lee, MBBS

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-142275

Published: 2020

Journal Articles

Role of Consolidation High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplant (ASCT) Support in Patients with Peripheral T-Cell Lymphoma Who Achieved Complete Remission (CR1) Following First Line Induction Chemotherapy

Lay Poh Khoo, BSc, Tiffany Tang, MD, Suk Teng Chin, BSc, Jeslin Ha, BSc, Colin Phipps, MBBS, MRCP, FRCPath, Yuh Shan Lee, MBBS, MRCP, FRCPath, Mohamad Farid, MD, Kevin Tay, MD, Miriam Tao, MD, Richard Hong Hui Quek, MD, Soon Thye Lim, MD

Blood (2016) 128 (22): 4640.

https://doi.org/10.1182/blood.V128.22.4640.4640

Published: 2016

Journal Articles

Time from Diagnosis to Initiation of Curative Chemotherapy Affects Outcomes in DLBCL - Data from a Large Asian Cohort

Colin Phipps, MBBS, MRCP, FRCPath, Yuh Shan Lee, MBBS, MRCP, FRCPath, Chandramouli Nagarajan, MBBS, MD MRCP, Yunxin Chen, MBBS, MRCP, FRCPath, Allan ZK Goh, Lay Poh Khoo, BSc, Kevin Tay, MD, Miriam Tao, MD, Richard Quek, Tiffany Tang, MD, Mohamad Farid, MD, Soon Thye Lim, MBBS, MRCP, Sathish Kumar Gopalakrishnan, FRCPath, Nicholas F Grigoropoulos, MRCP, FRCPath, Yvonne Loh, MBBS, MRCP, Daryl Tan, MBBS, MRCP, William YK Hwang, MBBS, MRCP, FRCP, Yeow Tee Goh, MD

Blood (2016) 128 (22): 1871.

https://doi.org/10.1182/blood.V128.22.1871.1871

Published: 2016

Journal Articles

A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL)

Yeow-Tee Goh, MBBS,MMed, William YK Hwang, FRCP, FAMS, MMed, MRCP, MBBS, Colin Phipps Diong, Yap chun Hsien, bsc, Kevin Tay, MD, Soon Thye Lim, MBBS, MRCP, Yuh Shan Lee, MBBS, MRCP, Soo Chin Ng, MD, S Fadilah, MBBS, Won Seog Kim, Daryl Tan, MD

Blood (2014) 124 (21): 503.

https://doi.org/10.1182/blood.V124.21.503.503

Published: 2014

Journal Articles

Incorporation of Bortezomib Into Frontline Treatment of Multiple Myeloma According to Risk Stratification Shifts the Most Significant Prognostic Indicator From Cytogenetics to the Quality of Induction Response

Daryl Tan, MBBS, MRCP, Bernard K.C Yap, BSc, Lionel K.Y See, BSc, Grace Kam, MBBS, MRCP, Colin Phipps Diong, Yuh Shan Lee, MBBS, MRCP, Dawn Mya, MBBS, MRCP, William Hwang, MBBS, FRCP, FAMS, Yeow Tee Goh, MD

Blood (2010) 116 (21): 3056.

https://doi.org/10.1182/blood.V116.21.3056.3056

Published: 2010

NARROW

Phase I/II Dose-Escalation Study of Lenalidomide in Combination with R-GDP for Treatment of Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Followed By Maintenance Lenalidomide

Role of Consolidation High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplant (ASCT) Support in Patients with Peripheral T-Cell Lymphoma Who Achieved Complete Remission (CR1) Following First Line Induction Chemotherapy

Time from Diagnosis to Initiation of Curative Chemotherapy Affects Outcomes in DLBCL - Data from a Large Asian Cohort

A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL)

Incorporation of Bortezomib Into Frontline Treatment of Multiple Myeloma According to Risk Stratification Shifts the Most Significant Prognostic Indicator From Cytogenetics to the Quality of Induction Response

Email alerts

ASH Publications

American Society of Hematology

Phase I/II Dose-Escalation Study of Lenalidomide in Combination with R-GDP for Treatment of Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Followed By Maintenance Lenalidomide

Role of Consolidation High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplant (ASCT) Support in Patients with Peripheral T-Cell Lymphoma Who Achieved Complete Remission (CR1) Following First Line Induction Chemotherapy

Time from Diagnosis to Initiation of Curative Chemotherapy Affects Outcomes in DLBCL - Data from a Large Asian Cohort

A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL)

Incorporation of Bortezomib Into Frontline Treatment of Multiple Myeloma According to Risk Stratification Shifts the Most Significant Prognostic Indicator From Cytogenetics to the Quality of Induction Response

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only